Thursday, October 4, 2012
A Memorial Sloan-Kettering Cancer Center team has
shown that a transferrin-based PET imaging
agent detected prostate cancer in mice with greater sensitivity than 18F-labeled fluorodeoxyglucose.1
The new agent also detected a precancerous prostate condition that is not
amenable to existing imaging technologies. The team now plans to take the agent
into Phase I testing to detect prostate cancer.
Despite the ability of 89Zr-DFO-transferrin to
detect PIN, the agent probably would not find utility as a tool to screen for
the risk of prostate cancer because "there is no unmet clinical need to
detect and image PIN," Lewis said.
Haas, M.J. SciBX 5(39); doi:10.1038/scibx.2012.1022
Published online Oct. 4, 2012
1. Holland, J.P. et al.
Nat. Med.; published online Sept. 23, 2012; doi:10.1038/nm.2935
Contact: Jason S. Lewis, Memorial Sloan-Kettering Cancer Center, New
Contact: Charles L. Sawyers, same affiliation as above
2. Som, P. et al. Eur.
J. Nucl. Med. 8, 491-494 (1983)
3. Prost, A.C. et al.
Int. J. Rad. Appl. Instrum. B 17, 209-216 (1990)
4. Aloj, L. et al. J.
Nucl. Med. 40, 1547-1555 (1999)
5. Vavere, A.L. &
Welch, M.J. J. Nucl. Med. 46, 683-690 (2005)
6. Holland, J.P. et al.
Nucl. Med. Biol. 36, 729-739 (2009)
7. Holland, J.P. et al.
J. Nucl. Med. 51, 1293-1300 (2010)
AND INSTITUTIONS MENTIONED
Howard Hughes Medical Institute, Chevy Chase, Md.
Memorial Sloan-Kettering Cancer Center, New York, N.Y.
National Institutes of Health, Bethesda, Md.
Sloan-Kettering Institute, New York, N.Y.